SCHEMBL14955218

SCHEMBL14955218

NC(=O)c1ncc(NC2CCC(N)CC2)nc1Nc1cccc(-c2ncccn2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 2/20 0.54
▸ PIM1 P11309 2/20 0.54
▸ PIM2 Q9P1W9 2/20 0.54
▸ ALK Q9UM73 2/20 0.54
▸ CDC7 O00311 1/20 0.54
▸ PLK4 O00444 1/20 0.54
▸ CHEK1 O14757 1/20 0.54
▸ PDPK1 O15530 1/20 0.54
▸ DAPK3 O43293 1/20 0.54
▸ DYRK3 O43781 1/20 0.54
▸ JAK2 O60674 1/20 0.54
▸ ROCK2 O75116 1/20 0.54
▸ RPS6KA5 O75582 1/20 0.54
▸ PRKD3 O94806 1/20 0.54
▸ MAP4K4 O95819 1/20 0.54
▸ PAK4 O96013 1/20 0.54
▸ CHEK2 O96017 1/20 0.54
▸ ABL1 P00519 1/20 0.54
▸ PRKCG P05129 1/20 0.54
▸ LCK P06239 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14961934 1.00 BTK (0.54) BTKPIM1PIM2ALKCDC7
SCHEMBL14955221 1.00 BTK (0.54) BTKPIM1PIM2ALKCDC7
SCHEMBL14955659 0.86 SYK (0.51) BTKPIM1PIM2ALKCDC7
SCHEMBL14955662 0.86 SYK (0.51) BTKPIM1PIM2ALKCDC7
SCHEMBL14956594 0.85 MAPK1 (0.73) BTKPIM1PIM2ALKCDC7
SCHEMBL14961933 0.85 MAPK1 (0.73) BTKPIM1PIM2ALKCDC7
SCHEMBL14956595 0.85 MAPK1 (0.73) BTKPIM1PIM2ALKCDC7
SCHEMBL14956724 0.85 JAK2 (0.75) BTKPIM1PIM2ALKCDC7
SCHEMBL14956102 0.83 SYK (0.75) BTKPIM1PIM2ALKCDC7
SCHEMBL14961937 0.83 SYK (0.75) BTKPIM1PIM2ALKCDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131040-A1 PYRAZINE KINASE INHIBITORS SYK, ZAP70, LCK BTK 5/4885PIM1 206/4885PIM2 176/4885
US-20140309209-A1 Pyrazine Kinase Inhibitors SYK, ZAP70, LCK BTK 5/4885PIM1 206/4885PIM2 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback